CJC no-DAC / Ipamorelin Protocol

Evidence Level: Investigational / Theoretical

Primarily preclinical or very limited human data — mechanism-based reasoning more than a demonstrated clinical effect. Treat as investigational.

Human evidence: No combination-specific trials — see individual CJC-1295 and Ipamorelin entries.

Animal evidence: No combination-specific animal trials.

Introduction & Mechanism of Action

Combination GHRH analog and ghrelin-receptor agonist studied for growth-hormone pulse research.

Pairs a GHRH-receptor agonist (CJC-1295 No DAC) with a ghrelin-receptor agonist (Ipamorelin) — two distinct receptor pathways studied together for an additive GH-pulse effect, a common combination rationale in this research area.

Receptors/targets: GHRH receptor, Ghrelin receptor (GHS-R1a)

Areas of Research Interest

• Growth-hormone pulse research
• Recovery and sleep-quality studies

Benefits Reported in Research

• Growth-hormone pulse research
• Recovery and sleep-quality studies

Reported Research Dosing Range

The figures below are cited from published research literature and protocol references — they describe what has been studied, not a personal prescription or instruction.

Reported range: 100–300 mcg per component

Reported frequency: 1–2× daily, subcutaneous

Reported cycle duration: 8–12 weeks

Escalation & maintenance: A dedicated weekly escalation and maintenance schedule specific to this peptide has not yet been published here — follow the dose range and frequency above, titrating conservatively from the low end, and consult a physician before adjusting.

Research Reference Data

Published research on CJC no-DAC / Ipamorelin reports administration at 100–300 mcg per component via subcutaneous route. The table below cites that published research — it is not an individualized instruction.

Reconstitution Reference

Published research protocols reconstitute a 10 mg vial with 2 mL bacteriostatic water, yielding a concentration of 5.00 mg/mL. This is cited reference information, not a personalized preparation instruction — use the general research calculator below for your own reference computation.

Research Protocol Timeline

A reference summary of how this compound is described across published research — formulation, reported administration, and reported cycle length.

Dilution Guide

Reconstitute with 2 mL bacteriostatic water

Bacteriostatic Water (BAC Water) is the only recommended diluent. Do not dilute with sterile water, normal saline, lidocaine, or any other solution unless explicitly specified by the manufacturer.

Handling Guide

General laboratory handling practice cited for reference — not a personalized instruction. Any human use should follow the guidance of a licensed physician.

Wash hands and clean the injection site with an alcohol swab. Pinch a fold of skin and insert the needle at a 45–90° angle for standard subcutaneous injection (abdomen, thigh, or upper arm). Inject slowly, withdraw, and apply gentle pressure. Rotate injection sites to reduce irritation, and dispose of needles in an approved sharps container.

Storage

Store lyophilized (powder) vials in a freezer at -20°C, protected from light. Once reconstituted with bacteriostatic water, refrigerate at 2–8°C and use within the timeframe recommended in your supplier documentation — typically 2–4 weeks.

Monitoring

Monitor for injection-site reactions and the side effects listed above. Stop use and consult a physician if severe or persistent reactions occur. This is a general monitoring guideline, not a personalized medical monitoring plan.

Side Effects

• Flushing
• Injection-site reaction
• Water retention

Contraindications

• Active malignancy (theoretical concern)
• Pregnancy

Drug interactions

• Not characterized specifically for the combination beyond the individual components

Safety

• Combines the individually limited safety profiles of both components
• Frequent dosing burden

Combination-specific trials are essentially absent; see individual CJC-1295 and Ipamorelin entries for their respective evidence bases.

Expected Results & Comparison

This is the classic "GHRH + GHRP" combination rationale — CJC-1295 No DAC stimulates GHRH-receptor signaling while Ipamorelin stimulates the separate ghrelin-receptor pathway. Combination-specific trials are essentially absent; see individual entries for what is known about each component.

References

Continue